Key result
Routine aspirin use for everyone older than 50 lacks sufficiently strong evidence of benefit to justify widespread public recommendation.
Why the study?
Should aspirin be recommended for everyone older than 50?
Should aspirin be recommended for everyone older than 50?
Answers are grounded in this paper and cite their sources.
This editorial argues against recommending aspirin for everyone over 50, citing insufficient evidence of benefit.
Current population screening for vascular disease is neither efficient nor effective. Peter Elwood and colleagues believe we should have a public information strategy highlighting the benefits (and risks) of aspirin for older people, but Colin Baigent argues that the evidence of benefit is not yet strong enough
No takes yet. Share an insight, caveat, or question.
Colin Baigent (2005) studied this question. Routine aspirin use for everyone older than 50 lacks sufficiently strong evidence of benefit to justify widespread public recommendation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: